Package Leaflet: Information for the User
Fortecortin 40 mg/5 ml Solution for Injection
Dexamethasone phosphate
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack:
The dexamethasone phosphate contained in Fortecortin is a corticosteroid (glucocorticoid) derived from cortisone. It regulates many of the body's metabolic processes with anti-inflammatory and immunosuppressive activity.
Fortecortin is used by intravenous or intramuscular route for the treatment of:
Do not use Fortecortin:
Warnings and precautions
Administration of Fortecortin may induce adrenocortical insufficiency, especially if high doses are administered for a prolonged period.
Avoid sudden withdrawal of treatment, especially in prolonged treatments, as a corticosteroid withdrawal syndrome may appear, characterized by general malaise, weakness, and muscle pain, difficulty breathing, loss of appetite, nausea, vomiting, fever, decrease in blood pressure and blood glucose levels.
In certain special situations of physical stress during treatment with Fortecortin (e.g., febrile disorders, accidents, operations, childbirth), a temporary increase in the daily dose of corticosteroid may be necessary.
Fortecortin may increase the risk of contracting infections as well as hiding the signs of an infection and/or making its diagnosis difficult. Latent infections may reactivate during the use of corticosteroids.
In the following cases, close monitoring of treatment by your doctor will be necessary:
Long-term treatment with Fortecortin will only be established when it is strictly necessary and should be associated with specific treatment corresponding to each case.
Administration of Fortecortin may alter the value of some laboratory tests.
Especially with long-term treatment with high doses of Fortecortin, sufficient potassium intake and restricted salt intake should be considered, and potassium levels in the blood should be monitored.
Administration of high doses of dexamethasone may cause a decrease in heart rate in some patients.
Severe anaphylactic reactions (immune system hyperreaction) may occur.
If you have myasthenia gravis (severe muscle weakness), it may initially worsen during treatment with Fortecortin.
If the intravenous administration of Fortecortin is too rapid, a sensation of tingling or numbness may appear, which can last for a few minutes.
If Fortecortin is administered locally (by intramuscular route), undesired systemic effects may occur.
In postmenopausal women, Fortecortin may increase the risk of osteoporosis.
You should inform your doctor if you have any of the following symptoms of tumor lysis syndrome (TLS) such as muscle cramps, muscle weakness, confusion, vision loss or alteration, and difficulty breathing, in case you suffer from a malignant hematological process.
Children and adolescents
In children, the doctor should assess the benefits of treatment, as the use of glucocorticoids may affect their growth. Dexamethasone should not be used routinely in premature newborns with respiratory problems.
If dexamethasone is administered to a premature baby, it is necessary to monitor the function and structure of the heart.
Elderly
In patients over 65 years of age, the doctor should assess the benefits of treatment and possible risks, as it is possible that these patients may suffer more adverse effects, such as osteoporosis.
Using Fortecortin with other medicines
Inform your doctor or pharmacist if you are taking or have recently taken any other medicine, including those obtained without a prescription, homeopathic medicines, herbal remedies, and other health-related products, as it may be necessary to interrupt treatment or adjust the dose of some of them. Note that these instructions may also apply to medicines used before or after.
This is especially important if you are taking the following medicines:
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Pregnancy
Dexamethasone crosses the placenta. During pregnancy, especially in the first three months, treatment should only be administered after carefully weighing the risk/benefit ratio. Therefore, women should inform their doctor about an existing or suspected pregnancy. With long-term treatment with glucocorticoids during pregnancy, fetal growth disorders cannot be ruled out. If glucocorticoids are administered at the end of pregnancy, inadequate adrenal function may appear in the newborn, requiring substitution treatment with reduced doses in the newborn.
Newborns of mothers who received Fortecortin near the end of pregnancy may have low blood sugar levels after birth.
Breastfeeding
Glucocorticoids, including dexamethasone, pass into breast milk. So far, no harm has been reported in the infant. However, the need for administration during breastfeeding should be carefully examined. If high doses are necessary for medical reasons, breastfeeding should be interrupted. Consult your doctor immediately.
Fertility
The effects of Fortecortin on fertility have not been studied.
Driving and using machines
There are no data on how Fortecortin affects driving or operating machinery, so try not to perform tasks that require special attention until you verify how you tolerate the medicine.
Fortecortin contains sodium
This medicine contains less than 23 mg (1 mmol) of sodium per ampoule, so it is considered essentially "sodium-free".
Influence on laboratory tests
This medicine may alter the values of certain laboratory tests. Also, skin reactions in allergy tests may be masked.
Use in athletes
This medicine contains a component that may produce a positive result in doping tests.
Follow exactly the administration instructions of this medicine indicated by your doctor. Your doctor will set the doses individually. In case of doubt, consult your doctor or pharmacist again.
It should be taken into account that the dosage requirements are variable and should be individualized based on the disease and the patient's response.
Fortecortin is normally injected slowly (over 2-3 minutes) intravenously, but it can also be administered by intramuscular route. The dose and duration of treatment depend on the indication and severity of the disease to be treated. After obtaining an initial favorable response, your doctor will establish the most suitable maintenance dose for you. Reduction of the dose as well as suspension of treatment should always be done progressively.
Renal and hepatic insufficiency
No specific dose adjustment is necessary for patients with renal insufficiency.
In patients with hepatic insufficiency, comparatively lower doses may be sufficient, or the dose may need to be reduced.
Use in children and adolescents
Generally, the recommended daily dose in children is 0.08-0.3 mg/kg, depending on the severity and type of disease.
If you use more Fortecortin than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount used.
No acute intoxications with dexamethasone are known. In the case of overdose, it is expected that the adverse reactions described in this leaflet will occur to a greater extent.
If you stop treatment with Fortecortin
Do not stop treatment before it is indicated by your doctor or suddenly, as it may worsen your disease.
Dose reduction should be done progressively. Similarly, treatment suspension should always be done progressively.
Excessive rapid reduction of the dose after long-term treatment may cause symptoms such as muscle and joint pain. Your doctor will gradually reduce the dose you should use.
If you have any other doubts about the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The terms used to describe the frequency of side effects are as follows: Very common (may affect more than 1 in 10 people), common (may affect up to 1 in 10 people), uncommon (may affect up to 1 in 100 people), rare (may affect up to 1 in 1,000 people), very rare (may affect up to 1 in 10,000 people), frequency not known (cannot be estimated from the available data).
Due to the wide range of therapeutic use, dosage, and treatment duration, the frequency of Fortecortin's side effects is not known.
Blood and lymphatic system disorders: Alteration of blood cells (white blood cells and lymphocytes, among others).
Endocrine disorders: Adrenal suppression and induction of symptoms similar to Cushing's syndrome (moon face, truncal adiposity).
Eye disorders: Glaucoma (increased intraocular pressure), cataracts, worsening of corneal ulcer symptoms; eye infections, ptosis, pupil dilation (mydriasis), burning, scleral perforation, and in rare cases, reversible exophthalmos.
Visual disturbances, blurred vision, vision loss, with unknown frequency.
Gastrointestinal disorders: Gastric discomfort, ulcers, gastrointestinal bleeding, pancreatitis.
Immune system disorders: Hypersensitivity reactions, severe allergic reactions such as cardiac rhythm disorders, bronchospasm, blood pressure changes, circulatory failure, cardiac arrest.
Infections and infestations: Masking of infections, existing infections may worsen or reactivate, and new infections may appear, activation of intestinal parasitic diseases (strongyloidiasis).
Metabolism and nutrition disorders: Fluid retention (edema), potassium loss (which may cause arrhythmias), weight gain, increased blood sugar, diabetes mellitus, hypercholesterolemia, hypertriglyceridemia, increased appetite.
Musculoskeletal and connective tissue disorders: Muscle atrophy and weakness, myopathy, tendon disorders, osteoporosis, aseptic osteonecrosis, growth retardation in children, epidural lipomatosis.
Note: Excessive rapid reduction of the dose after long-term treatment may cause symptoms such as muscle and joint pain.
Nervous system disorders: Increased intracranial pressure (pseudotumor cerebri), increased spasms in epileptic patients or onset of epilepsy (convulsions).
Psychiatric disorders: Psychosis, mania, depression, hallucinations, emotional instability, irritability, increased activity, euphoria, anxiety, sleep disturbances, suicidal thoughts.
Reproductive system and breast disorders: Alteration of sex hormone secretion (amenorrhea, excessive hair growth, impotence).
Skin and subcutaneous tissue disorders: Acne, dermatitis around the mouth, stretch marks, skin atrophy, petechiae, telangiectasias, bruising, hirsutism, skin color changes.
Cardiac disorders: Heart failure.
Unknown frequency: thickening of the heart muscle (hypertrophic cardiomyopathy) in premature babies, which usually returns to normal after treatment is discontinued.
Vascular disorders: Hypertension, increased risk of arteriosclerosis and thrombosis, vasculitis (also as a symptom of withdrawal after long-term treatment), fragility of small blood vessels.
General disorders and administration site conditions: Delayed wound healing, hiccups.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if it is possible side effects not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Do not store at a temperature above 25°C. Keep the ampoules in the outer packaging to protect them from light.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging after CAD. The expiry date is the last day of the month indicated.
This medicine is for single use and must be administered immediately after opening. Any unused portion must be discarded.
Only clear and particle-free solutions should be used.
Do not use this medicine if you notice visible signs of deterioration.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and any unused medicines at the pharmacy's SIGRE Point. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medicines. This will help protect the environment.
Composition of Fortecortin 40 mg/5 ml
Each ml of injectable solution contains 8 mg of dexamethasone phosphate (as sodium dexamethasone phosphate, 8.75 mg)
Appearance of the Product and Package Contents
It is presented in the form of colorless type I glass ampoules. Packages containing 5, 25, and 50 ampoules of injectable solution.
Marketing Authorization Holder
LABORATORIOS ERN, S.A.
Perú, 228
08020 Barcelona
Spain
Manufacturer
LABORATORIOS ERN, S.A.
Gorgs Lladó, 188
08210 Barberá del Vallés, Barcelona, Spain
Date of the Last Revision of this Leaflet:January 2022
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
--------------------------------------------------------------------------------------------------------------------
This information is intended exclusively for healthcare professionals:
Fortecortin should not be mixed with other medicines due to a lack of compatibility data. It should preferably be administered directly by intravenous route or injected into the infusion line. However, the Fortecortin injectable solution is compatible with the following infusion solutions (250 ml and 500 ml each) and must be used within 24 hours: isotonic saline solution, Ringer's solution, and 5% glucose solution.
If Fortecortin is used in combination with infusion solutions, attention should be paid to the information on compatibility, contraindications, adverse reactions, and interactions provided by the manufacturers of the solutions.